Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Funda Meric-Bernstam

Showing results (451-460 of 643) with videos related to

Pageof 65
Sort By:
Cancer|October 21, 2023
Phase 1/2 trial of avelumab combined with utomilumab (4-1BB agonist), PF-04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignanciesAnne Knisely, Jibran Ahmed, Bettzy Stephen, et al.
Investigational New Drugs|October 20, 2017
Phase I study of the combination of crizotinib (as a MET inhibitor) and dasatinib (as a c-SRC inhibitor) in patients with advanced cancerShumei Kato, Denis L Jardim, Faye M Johnson, et al.
Molecular Oncology|May 28, 2025
Circulating tumor DNA monitoring and blood tumor mutational burden in patients with metastatic solid tumors treated with atezolizumabCharles Swanton, Russell W Madison, Candice Francheska B Tambaoan, et al.
Annals of Surgical Oncology|May 25, 2012
Biology, treatment, and outcome in very young and older women with DCISRosalinda Alvarado, Sara A Lari, Robert E Roses, et al.
Oncology|November 2, 2016
Post-Discharge Survival Outcomes of Patients with Advanced Cancer from the University of Texas MD Anderson Cancer Center Investigational Cancer Therapeutics (Phase I Trials) Inpatient UnitHolly Kinahan, Abhishek Maiti, Kenneth Hess, et al.
Clinical Genitourinary Cancer|August 4, 2014
MET abnormalities in patients with genitourinary malignancies and outcomes with c-MET inhibitorsDenis L F Jardim, Débora de Melo Gagliato, Gerald Falchook, et al.
JCO Precision Oncology|February 16, 2022
Monitoring of Dynamic Changes and Clonal Evolution in Circulating Tumor DNA From Patients With <i>IDH</i>-Mutated Cholangiocarcinoma Treated With Isocitrate Dehydrogenase InhibitorsMorten Lapin, Helen J Huang, Sharmeen Chagani, et al.
JCO Precision Oncology|February 1, 2022
Validation of <i>HER2</i> Amplification as a Predictive Biomarker for Anti-Epidermal Growth Factor Receptor Antibody Therapy in Metastatic Colorectal CancerKanwal Raghav, Jonathan M Loree, Jeffrey S Morris, et al.
Journal for Immunotherapy of Cancer|August 21, 2023
T-cell receptor beta variable gene polymorphism predicts immune-related adverse events during checkpoint blockade immunotherapyBettzy Stephen, Joud Hajjar, Shrutii Sarda, et al.
Oncotarget|November 21, 2017
Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Center experienceJennifer B Goldstein, Chad Tang, Kenneth R Hess, et al.
Pageof 65

Showing results (451-460 of 643) with videos related to

Sort By:
Pageof 65
Cancer|October 21, 2023
Phase 1/2 trial of avelumab combined with utomilumab (4-1BB agonist), PF-04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignanciesAnne Knisely, Jibran Ahmed, Bettzy Stephen, et al.
Investigational New Drugs|October 20, 2017
Phase I study of the combination of crizotinib (as a MET inhibitor) and dasatinib (as a c-SRC inhibitor) in patients with advanced cancerShumei Kato, Denis L Jardim, Faye M Johnson, et al.
Molecular Oncology|May 28, 2025
Circulating tumor DNA monitoring and blood tumor mutational burden in patients with metastatic solid tumors treated with atezolizumabCharles Swanton, Russell W Madison, Candice Francheska B Tambaoan, et al.
Annals of Surgical Oncology|May 25, 2012
Biology, treatment, and outcome in very young and older women with DCISRosalinda Alvarado, Sara A Lari, Robert E Roses, et al.
Oncology|November 2, 2016
Post-Discharge Survival Outcomes of Patients with Advanced Cancer from the University of Texas MD Anderson Cancer Center Investigational Cancer Therapeutics (Phase I Trials) Inpatient UnitHolly Kinahan, Abhishek Maiti, Kenneth Hess, et al.
Clinical Genitourinary Cancer|August 4, 2014
MET abnormalities in patients with genitourinary malignancies and outcomes with c-MET inhibitorsDenis L F Jardim, Débora de Melo Gagliato, Gerald Falchook, et al.
JCO Precision Oncology|February 16, 2022
Monitoring of Dynamic Changes and Clonal Evolution in Circulating Tumor DNA From Patients With <i>IDH</i>-Mutated Cholangiocarcinoma Treated With Isocitrate Dehydrogenase InhibitorsMorten Lapin, Helen J Huang, Sharmeen Chagani, et al.
JCO Precision Oncology|February 1, 2022
Validation of <i>HER2</i> Amplification as a Predictive Biomarker for Anti-Epidermal Growth Factor Receptor Antibody Therapy in Metastatic Colorectal CancerKanwal Raghav, Jonathan M Loree, Jeffrey S Morris, et al.
Journal for Immunotherapy of Cancer|August 21, 2023
T-cell receptor beta variable gene polymorphism predicts immune-related adverse events during checkpoint blockade immunotherapyBettzy Stephen, Joud Hajjar, Shrutii Sarda, et al.
Oncotarget|November 21, 2017
Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Center experienceJennifer B Goldstein, Chad Tang, Kenneth R Hess, et al.
Pageof 65